Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00801697 · ClinicalTrials.gov registry record · Phase 1
Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 192
- Enrollment target
NCT00801697 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 192 participants.
The verdict
NCT00801697, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 192 participants
- Enrollment target
Study Summary
This study will evaluate the safety and preliminary immune response to recombinant adenoviral serotype 35 and 5 HIV-1 vaccines in HIV-uninfected adults.
Interventions
- BIOLOGICAL DNA Vaccine
- BIOLOGICAL DNA Vaccine placebo
- BIOLOGICAL rAd35
- BIOLOGICAL rAd35 placebo
- BIOLOGICAL rAd5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2009-02 |
| Est. Completion | 2015-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00801697
The ClinicalTrials.gov registry entry for NCT00801697 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which DNA Vaccine is the first listed.
NCT00801697 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00801697 about?
NCT00801697 is a clinical study titled "Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector". This study will evaluate the safety and preliminary immune response to recombinant adenoviral serotype 35 and 5 HIV-1 vaccines in HIV-uninfected adults.
What is the current status of trial NCT00801697?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 192 participants. The study started on 2009-02. Estimated completion is 2015-04.
What interventions are being tested in trial NCT00801697?
The interventions under investigation include: DNA Vaccine (BIOLOGICAL), DNA Vaccine placebo (BIOLOGICAL), rAd35 (BIOLOGICAL), rAd35 placebo (BIOLOGICAL), rAd5 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00801697?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.